SCHEMBL24379914

SCHEMBL24379914

CSC(=O)NCCOCCN1CCN(C(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ FPR3 P25089 1/20 0.36
▸ FPR2 P25090 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ HTR4 Q13639 1/20 0.35
▸ DAO P14920 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ MAOB P27338 4/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ SLC5A7 Q9GZV3 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ DRD2 P14416 1/20 0.32
▸ DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26401932 0.99 MEN1 (0.39) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL22054371 0.86 SMN1; SMN2 (0.53) TP53SMN1; SMN2KMT2ALMNAALDH1A1
SCHEMBL23945709 0.85 TP53 (0.41) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL25972108 0.83 TP53 (0.40) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL21106866 0.83 MEN1 (0.41) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL24765441 0.83 MEN1 (0.41) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL21107025 0.83 MEN1 (0.45) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL21107592 0.82 MEN1 (0.47) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL22856287 0.82 MEN1 (0.47) TP53SMN1; SMN2FPR3FPR2MEN1
SCHEMBL25477805 0.81 SMN1; SMN2 (0.44) TP53SMN1; SMN2FPR3FPR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TP53 1474/4885SMN1; SMN2 2647/4885FPR3 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback